Objective: Experimental inflammation induces degradation of glycocalyx. The authors hypothesized that inflammation is an important determinant of glycocalyx degradation in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB).

Design: A prospective observational study.

Setting: Operation theater and intensive care unit of a university hospital.

Participants: Two separate prospective patient cohorts.

Interventions: Blood samples were collected at 5 perioperative time points in the trial cohort (30 patients) and only preoperatively in the preoperative cohort (35 patients). Plasma syndecan-1 (biomarker of glycocalyx degradation), interleukin-6 (IL-6), IL-8, and IL-10 were measured.

Measurements and Main Results: In the trial cohort, preoperative ranges were as follows: 0.8-198 ng/mL for syndecan-1; 0-902 pg/mL for IL-6; 0-314.9 pg/mL for IL-8, and 0-2,909 pg/mL for IL-10. Seven out of 30 patients were outliers in terms of plasma concentrations of syndecan-1 and all cytokines preoperatively. The increase of syndecan-1 was 2.7-fold, and those of IL-6 and IL-8 were both 2.5-fold. The increase of IL-10 was modest. Plasma syndecan-1 correlated with all cytokines preoperatively (IL-6: R = 0.66, p < 0.001; IL-8: R = 0.67, p = 0.001; IL-10: R = 0.73, p < 0.001) as well as at 6 hours postoperatively (IL-6: R = 0.49, p = 0.006; IL-8: R = 0.43, p = 0.02; IL-10: R = 0.41, p = 0.03) and on the postoperative morning (IL-6: R = 0.57, p = 0.001; IL-8: R = 0.37, p = 0.06; IL-10: R = 0.51, p = 0.005) but not intraoperatively. The preoperative findings of the trial cohort could be confirmed in the preoperative cohort.

Conclusions: In patients undergoing cardiac surgery with CPB, inflammation in terms of proinflammatory cytokines IL-6 and IL-8 and anti-inflammatory cytokine IL-10 is associated with glycocalyx degradation measured as plasma syndecan-1 concentrations.

© 2018 Elsevier Inc. All rights reserved.

Key Words: glycocalyx; inflammation; interleukin 6; interleukin 8; interleukin 10; syndecan-1; cardiopulmonary bypass

ENDOTHELIAL CELLS are covered by a 50-μm-thick layer of the glycocalyx, composed of glycoproteins and proteoglycans. The glycocalyx has a regulatory role in adhesion of leukocytes and platelets as well as coagulation and hemostasis on the endothelial surface. In an experimental setting, the proinflammatory cytokine TNFα mediates shedding of heparan sulfate, a major constituent of proteoglycans, and of syndecan-1, the backbone of the glycoprotein meshwork, from the glycocalyx. This suggests that systemic
inflammation may threaten integrity of the endothelial glyco-
calyx significantly. Hydrocortisone decreases glycoalyx deg-
radation in an ex vivo model of cardiac reperfusion.6,7
Cardiopulmonary bypass (CPB) results in prompt degrada-
tion of the glycoalyx, which coincides with the CPB-induced systemic inflammatory response.8,9 There is wide variation even in baseline plasma concentrations of degradation mole-
cules of the glycoalyx in cardiac surgical patients.10 Therefore, mathematical expression of relative changes of glycoalyx degradation markers as multiples of the respective baseline values has been applied in previous studies.8,9,11 Thus, the interrelationship between glycoalyx degradation and activation of inflammation in previous studies is difficult to interpret. In the present study the authors hypothesized that CPB-induced inflammation is associated with glycoalyx degrada-
tion, as measured by syndecan-1, in patients undergoing cardiac surgery with CPB.

Methods
The study consists of 2 separate patient series, both of which were approved by the local ethics committee. All patients of both series gave written informed consent to participate in the study. The patients of the first patient cohort (trial cohort) originated from a previous trial comparing 6% hydroxyethyl starch (HES) 130/0.42 solution (Tetraspan, B. Braun Medical, Helsinki, Finland) and Ringer’s acetate solution (Ringer-acetat; Baxter, Helsinki, Finland) for CPB priming in cardiac surgery (ClinicalTrials.gov; NCT00797589).12 The CPB priming fluid comprised of either 2,000 mL of Ringer’s acetate solution only (n = 18) or 20 mL/kg of HES solution with additional Ringer’s acetate solution up to 2,000 mL (n = 12). Otherwise, only Ringer’s acetate solution was administered to all patients intraoperatively. Postopera-
tively, all patients received Ringer’s acetate solution as a background infusion of 30 to 50 mL/kg and, if needed, 4% albumin solution (Albumin norm 40 g/L, Octapharm, Stockholm, Sweden) for hypovolemia. Anesthesia was induced with alfentanil and etomidate and maintained with sevoflurane and alfentanil infusion. Fluid and blood product administra-
tion, management of hemodynamics, and heparin and prot-
amine dosing were protocolized. Mean arterial pressure was targeted to 70 mmHg when off CPB and to 50 to 60 mmHg during CPB. CPB was performed using nonpulsatile pump (2-2.4 L/min/m²) and membrane oxygenator with mild hypo-
thermia (nasopharyngeal temperature of 30°C-33°C).12 Plasma samples of 5 patients were missing. Thus, the trial cohort consisted of 30 patients. Patients with preoperative coagulation disorders; renal or hepatic failure; preoperative left ventricular ejection fraction lower than 40%; or treatment with warfarin, heparin, low molecular weight heparin, or clo-
pidogrel within the previous 5 days were excluded.12 Blood samples were drawn into polypropylene tubes con-
taining 3.2% buffered citrate (BD Vacutainer, BD Diagnostics, Plymouth, UK) via a nonheparinized radial arterial catheter at the following time points: (1) before induction of anesthesia; (2) after protamine administration; (3) immediately before leaving the operation theater; (4) 6 hours postoperatively; and (5) at the first postoperative morning. To repeat the preoperative findings of the trial cohort, in the second patient series (preoperative cohort), a preoperative blood sample was drawn before the anesthesia induction into polypropylene tubes con-
taining 3.2% buffered citrate (BD Vacutainer, BD Diagnos-
tics) via a nonheparinized radial arterial catheter in 35 consecutive patients undergoing cardiac surgery. The blood sample tubes were immediately centrifuged and separated plasma was stored at −70°C until analysis of plasma concentra-
tions of interleukin-6 (IL-6), interleukin-8 (IL-8), interleu-
kin-10 (IL-10) (Quantikine, R&D Systems, Abington, UK), and syndecan-1 (Diacalone SAS, Besancon, France). The analyses were preformed using unthawed samples within 6 months after end of patient recruitment of each trial. C-reactive protein (CRP) and leukocyte count were measured preoperatively as part of standard clinical routine in the clinical laboratory of the hospital. The detection limit of CRP was 3 mg/L.

Data were analyzed with SPSS Version 24 for Windows program (IBM Corp, Armonk, NY). Kolmogorov-Smirnov test and visual inspection of histograms were used for assessing data distributions. Plasma concentrations of syndecan-1 and all cytokines did not show normal distribution. After loga-
rithmic transformation, plasma concentrations of the trial cohort study groups were normally distributed. There were no differences of syndecan-1 or any cytokines between the HES and Ringer acetate groups in trial cohort in analysis of vari-
ance for repeated measures. Thus, patients of the trial cohort were pooled as a single group in further statistical analyses. In further analyses, nonparametric tests were used without loga-
rithmic transformation. Friedman test was used for testing dif-
ferences as a function of time and Spearman’s test for bivariate correlations. P values less than 0.05 were considered statistically significant. Data are expressed as medians and interquartile ranges or depicted as box plots or as individual values in scatter plots.

Results

Trial Cohort
Patient characteristics and procedure data of the trial cohort are presented in the Table 1. There were no major complica-
tions in any patient. In the trial cohort, 7 patients were outliers in terms of plasma concentrations of syndecan-1 and all cyto-
kines preoperatively (Fig 1). Plasma concentrations of synde-
can-1 (p = 0.001) and all cytokines (IL-6: p < 0.001; IL-8: p < 0.001; IL-10: p < 0.03) increased significantly as a function of time (Fig 2). Perioperative plasma concentrations of synde-
can-1 and all cytokines followed a level that was predefined by the preoperative level. In other words, perioperative plasma concentrations of syndecan-1 and all cytokines correlated with the corresponding concentrations at all later time points (data not shown). These correlations were strongest at the postoper-
avative morning (preoperative versus postoperative morning: syndecan-1: R = 0.71, p = 0.004; IL-6: R = 0.58, p = 0.001; IL-8: R = 0.65, p < 0.001; IL-10: R = 0.76, p < 0.001). Plasma
syndecan-1 correlated significantly with all cytokines preoperatively (Fig 1) and again at 6 hours postoperatively (syndecan-1 versus IL-6: R = 0.49, p = 0.006; syndecan-1 versus IL-8: R = 0.43, p = 0.02; syndecan-1 versus IL-10: R = 0.41, p = 0.03) and on the postoperative morning (syndecan-1 versus IL-6: R = 0.57, p = 0.001; syndecan-1 versus IL-8: R = 0.37, p = 0.06; syndecan-1 versus IL-10: R = 0.51, p = 0.005) but not intraoperatively.

In the trial cohort, preoperative CRP was over the detection limit of 3 mg/L in only 5 patients and ranged from 4 to 13 mg/L. Preoperative leukocyte count was 7.0 (5.9-8.0) E9/l and the highest value was 10.4 E9/l. Preoperative CRP or leukocyte count did not correlate with either preoperative syndecan-1 or cytokine concentrations (data not shown).

Preoperative Cohort

To repeat the aforementioned preoperative findings, the authors measured preoperative plasma syndecan-1 and cytokine concentrations in series of 35 patients independent of the trial cohort. Patient characteristics and procedure data of this preoperative cohort are presented in Table 1. In this series, the range of plasma concentrations of syndecan-1 was 0 to 122 ng/mL and those of IL-6 0 to 1,165 pg/mL, IL-8 0 to 399 pg/mL and IL-10 0 to 2,762 pg/mL. Three patients were outliers in terms of plasma cytokine concentrations. Syndecan-1 levels correlated with all cytokines (IL-6: R = 0.71, p < 0.001; IL-8: R = 0.70, p < 0.001; IL-10: R = 0.64, p < 0.001). Preoperative CRP was over the detection limit of 3 mg/L in only 8 patients and ranged from 4 to 13 mg/L. Preoperative leukocyte count was 6.8 (6.0-8.0) E9/l and the highest value was 12.2 E9/l. Preoperative CRP or leukocyte count did not correlate with either preoperative syndecan-1 or cytokine concentrations (data not shown).

Discussion

CPB induces a systemic inflammatory reaction. Degradation of the glycocalyx in terms of plasma syndecan-1 concentrations has been well documented in both adult and pediatric cardiac surgery. There were significant correlations

![Fig 1](image1.png)  
Fig 1. Preoperative correlations of plasma syndecan-1 concentrations with interleukin-6, interleukin-8, and interleukin-10 concentrations.

![Fig 2](image2.png)  
Fig 2. Plasma concentrations of syndecan-1, interleukin-6, interleukin-8, and interleukin-10 as a function of time. Time points: (1) before induction of anesthesia; (2) after protamine administration; (3) immediately before leaving the operation theater; (4) 6 hours postoperatively; and (5) at the first postoperative morning.

<table>
<thead>
<tr>
<th>Age, y</th>
<th>73 (68-80)</th>
<th>67 (56-73)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex male/Female, n</td>
<td>18/12</td>
<td>26/9</td>
</tr>
<tr>
<td>Surgery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CABG, n</td>
<td>0</td>
<td>16</td>
</tr>
<tr>
<td>Aortic reconstruction, n</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>AVR, n</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>MVR, n</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>MVR + CABG, n</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>AVR + MVR, n</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>CPB time, min</td>
<td>146 (125-159)</td>
<td></td>
</tr>
<tr>
<td>Aortic cross-clamping time, min</td>
<td>111 (99-127)</td>
<td></td>
</tr>
<tr>
<td>Intraoperative fluid balance, mL</td>
<td>3,987</td>
<td>(2,614-5,813)</td>
</tr>
<tr>
<td>Postoperative fluid balance till the first postoperative morning, mL</td>
<td>1,266</td>
<td>(536-2,218)</td>
</tr>
<tr>
<td>Cumulative fluid balance till the first postoperative morning, mL</td>
<td>5,601 (4,209-6,681)</td>
<td></td>
</tr>
</tbody>
</table>

NOTE. The data are presented as medians and interquartile ranges or as numbers.

Abbreviations: AVR, aortic valve replacement; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; MVR, mitral valve replacement.
between plasma cytokine and syndecan-1 concentrations both pre- and postoperatively. In experimental condition, TNFα-mediated syndecan-1 shedding could be prevented with hydrocortisone pretreatment. Hydrocortisone reduced glycocalyx breakdown also in ex vivo model of cardiac ischemia-reperfusion. Likewise, it has been recently shown that high-dose methylprednisolone conserved glycocalyx in neonates undergoing correction of complex congenital heart defects.

Preoperatively in the trial cohort, there were 7 outlying patients with high plasma concentrations of both syndecan-1 and all cytokines. As preoperative plasma concentrations of all these biomarkers correlated with the corresponding concentrations at all later time points, perioperative plasma concentrations of syndecan-1 and all cytokines were significantly predefined by the preoperative level. A wide distribution of preoperative syndecan-1 concentrations has been observed previously. In the present study, the minimum and maximum preoperative syndecan-1 concentrations were 0.8 pg/mL and 198.0 pg/mL, respectively. This resulted in up to 247-fold difference of plasma syndecan-1 between the patients already preoperatively. As comparison, the median peak increase of syndecan-1 in the trial cohort as a function of time was only 2.7-fold. This indicates that syndecan-1 concentrations during cardiac surgery vary substantially more between patients than within patients (ie, within different time points). This makes plasma syndecan-1 difficult to use as a biomarker. Indeed, in the pioneering study by Rehm et al. and in later studies both in adults and children, expression of fold-increase as multiples of the baseline value has been applied instead of absolute values.

Seven out of 30 patients in the trial cohort were in a proinflammatory state already preoperatively in terms of increased plasma concentrations of proinflammatory cytokines. The outlying patients presented preoperative IL-8 concentrations comparable to the concentrations in severe sepsis and higher than in severe acute pancreatitis. Furthermore, in the same patients, preoperative IL-6 was at the level previously detected in cardiogenic shock and at the lower range of IL-6 observed in severe sepsis. Direct comparison of cytokine levels between different studies should be done with caution, because different commercial enzyme-linked immunosorbent assay kits may give slightly different results. Still, it can be concluded that the preoperative proinflammatory cytokine concentrations in some of the authors’ patients were high. In the trial cohort, preoperative cytokine concentrations correlated with the concentrations on the postoperative morning. This implies that when the perioperative proinflammatory insult of CPB has ceased, the patients returned to their preoperative state. Importantly, the authors were able to repeat the preoperative findings in a separate cohort of 35 patients. First, the upper ranges of all 3 cytokines were comparable to the ones in the trial cohort. Second, 3 out of 35 patients presented with substantially high cytokine and syndecan-1 concentrations. Third, syndecan-1 correlated significantly with all measured cytokines.

Although surprising, corresponding observations actually can be found in the existing literature. Marano et al found that 10 out of 36 patients undergoing elective coronary artery bypass grafting presented with high TNFα concentrations already before induction of anesthesia. Furthermore, a wide distribution of preoperative IL-8 concentrations comparable to the present results has been reported in elective cardiac surgery. The fact that the distribution of the latter reference study was rightward skewed (standard deviation 2.4 times as high as the mean) implies that, like in the present study, there must have been some outliers with especially high IL-8 concentrations. Preoperative plasma syndecan-1 concentrations with outlying patients and distribution similar to the present study have been reported in cardiac surgery. In both cohorts of the present study, preoperative CRP and leukocyte counts were within normal limits or in some patients only modestly increased and did not correlate with preoperative cytokine or syndecan-1 concentrations. Possibly due to small patient number, the authors could not find any association between available clinical data and syndecan-1 and cytokine concentrations. The authors cannot offer any pathophysiological mechanism for the subgroup of patients with substantially high proinflammatory cytokines and syndecan-1 already preoperatively.

As a weakness of this observational study, only association between inflammatory reaction and glycocalyx degradation was detected. This does not necessarily mean a causal relationship, although experimental and some clinical evidence for such a relationship exists. Furthermore, 2 treatment arms of a previous clinical trial were pooled for this study. However, the major findings (ie, the preoperative pro-inflammatory state of a subgroup of patients and the association of inflammation to glycocalyx degradation) were based mainly on measurements at the preoperative time point. This time point was not hampered with differences of the treatment arms. As a strength, the preoperative findings of the trial cohorts were confirmed in a separate independent patient series.

As a conclusion, a subgroup of patients undergoing elective cardiac surgery presented an inflammatory state in terms of proinflammatory cytokines IL-6 and IL-8 and anti-inflammatory cytokine IL-10 already preoperatively. Furthermore, this inflammation was associated with glycocalyx degradation measured as plasma syndecan-1 concentrations. The clinical significance and mechanism behind these phenomena is to be studied.

References